Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)
Top Cited Papers
Open Access
- 14 June 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (4), 894-903
- https://doi.org/10.1093/ndt/gfac198
Abstract
Despite available interventions, people with type 2 diabetes (T2D) remain at risk of chronic kidney disease (CKD). Finerenone, a potent and selective nonsteroidal mineralocorticoid receptor antagonist, and sodium–glucose cotransporter 2 inhibitors (SGLT2is) can reduce both kidney and cardiovascular risks in people with CKD and T2D. Here we outline the design of a study to investigate whether dual therapy with finerenone and an SGLT2i is superior to either agent alone. CONFIDENCE (NCT05254002) is a randomized, controlled, double-blind, double-dummy, international, multicenter, three-armed, parallel-group, 7.5 - to 8.5-month, Phase 2 study in 807 adults with T2D, stage 2–3 CKD and a urine albumin:creatinine ratio (UACR) ≥300–<5000 mg/g. The primary objective is to demonstrate that 6 months of dual therapy comprising finerenone and the SGLT2i empagliflozin is superior for reducing albuminuria versus either agent alone. Interventions will be once-daily finerenone 10 mg or 20 mg (target dose) plus empagliflozin 10 mg, or empagliflozin 10 mg alone, or finerenone 10 mg or 20 mg (target dose) alone. The primary outcome is a relative change from baseline in UACR among the three groups. Secondary outcomes will further characterize efficacy and safety, including changes in estimated glomerular filtration rate and incident hyperkalemia. CONFIDENCE is evaluating the safety, tolerability and efficacy of dual use of finerenone and an SGLT2i in adults with CKD and T2D. Should an additive effect be shown, early and efficient intervention with dual finerenone and SGLT2i therapy could slow disease progression and provide long-term benefits for people with CKD and T2D.Keywords
Funding Information
- Bayer AG
This publication has 40 references indexed in Scilit:
- Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic ActivityHypertension, 2018
- Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trialThe Lancet Diabetes & Endocrinology, 2017
- Diabetic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2017
- Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1Journal of the American Society of Nephrology, 2017
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes MellitusCirculation, 2016
- Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal IschemiaJournal of the American Society of Nephrology, 2016
- KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 UpdateAmerican Journal of Kidney Diseases, 2012
- Modification of the CKD Epidemiology Collaboration (CKD-EPI) Equation for Japanese: Accuracy and Use for Population EstimatesAmerican Journal of Kidney Diseases, 2010
- Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysisThe Lancet, 2010
- A New Equation to Estimate Glomerular Filtration RateAnnals of Internal Medicine, 2009